Company advances its three-pillar soft tissue surgery platform on the strength of five years of clinical validation and growing market demand

DURHAM, N.C., April 21, 2026 — Deep Blue Medical Advances, a surgical device company redefining outcomes in soft tissue surgery, today announced the closing of an oversubscribed $5.6 million Series A financing round and the promotion of Lou Fuqua to Chief Operating Officer.

The proceeds will fuel the commercial launch of Deep Blue’s biosynthetic absorbable T-Line® Mesh, support expansion into aesthetic and breast applications, and deepen already extensive relationships with key opinion leaders and hospital systems.

Deep Blue’s platform is purpose-built to address suture pull-through — a leading cause of soft tissue surgical failure across multiple anatomies — through its proprietary T-Line Mesh, Suture, and Aesthetic Scaffold product lines.

“This oversubscribed round reflects strong investor confidence in our platform and the clinical evidence behind it,” said CEO Bill Perry. “With 18 peer-reviewed publications, 21 issued patents, and more than 20,000 patented lockstitches and extensions implanted over five years — including multi-center long-term follow-up demonstrating high efficacy and excellent safety — Deep Blue is exceptionally well-positioned to scale. The pipeline is full, the evidence is strong, and the timing is right.”  

Lou Fuqua Promoted to Chief Operating Officer

Mr. Fuqua, previously Senior Vice President, brings extensive experience scaling medical device startups into established commercial organizations. His expertise spans quality, regulatory affairs, product development, and manufacturing. In his expanded role, he will lead execution across these functions as the company moves into a key growth phase.

“Suture pull-through and surgical failure represent a significant, underappreciated problem — and we have a compelling solution,” said Mr. Fuqua. “I’m proud of what this team has built and excited about what comes next.”  

About Deep Blue Medical Advances

Deep Blue Medical Advances is transforming soft tissue surgery through next-generation surgical devices engineered for optimal tissue tension, reinforcement, and defect closure. The company’s portfolio includes the T-Line Mesh, Suture, and Aesthetic Scaffold product lines, backed by robust clinical data and a growing intellectual property portfolio.

SOURCE Deep Blue Medical Advances, Inc.

• Company is developing prefabricated nuclear power plants designed for faster, more predictable deployment
• Financing was led by VXI Capital with significant backing from Engine Ventures and participation from other existing investors, including At One Ventures and Tamarack Global
• Proceeds will support long-lead equipment procurement, project development and corporate growth
• The Nuclear Regulatory Commission recently approved Blue Energy’s innovative approach to nuclear plant construction

CHEVY CHASE, Md., April 21, 2026 — Blue Energy, a developer of financeable, prefabricated nuclear power plants, today announced that it has raised $380 million in financing to advance its turnkey approach to nuclear plant development. The fundraise was led by VXI Capital with significant backing from Engine Ventures and participation from other existing investors, including At One Ventures and Tamarack Global. Proceeds will support procurement of long-lead equipment, project development activities, and general corporate purposes.

Blue Energy is developing prefabricated nuclear power plants designed to be compatible with leading reactor technologies and delivered on an accelerated timeline in as little as 48 months. The complexity of bespoke nuclear plant construction has historically contributed to delays, cost overruns, and financing uncertainty. This uncertainty and risk have sidelined private capital and created an overreliance on taxpayer dollars and consumer rate hikes. Blue Energy believes it can address those challenges through an innovative development model centered on reducing construction risk through centralized advanced manufacturing, skilled labor and more predictable schedules.

“This funding marks an important step in Blue Energy’s mission to make new nuclear more deployable, predictable, and financeable,” said Blue Energy CEO and Co-Founder Jake Jurewicz. “Blue Energy is poised to deliver a significantly de-risked product and finally attract the private capital that nuclear deployment has historically struggled to secure. And for the first time, a nuclear project is designed so that it doesn’t need to rely primarily on taxpayer dollars and ratepayers to backstop risk. By combining offsite prefabrication, standardized plant delivery and a disciplined development model, we believe Blue Energy can reduce cost and compress timelines with the goal of making nuclear power competitive with fossil fuel and renewables – all without sacrificing safety. Blue Energy is developing a nuclear power product designed to scale at a time when the world needs it most.”

By unlocking project financing, Blue Energy plans to deliver on the promise of nuclear power by prefabricating modular plants offsite at existing fab yards from proven components with fixed-price contracting and reliable timelines – aiming to make nuclear power more predictable, faster and more affordable. Blue Energy expects to begin construction on its first project in Texas in Q3 2026. The project is designed to deliver up to 1.5 gigawatts (GW) of affordable, reliable power to large-scale electricity customers, including artificial intelligence (AI) datacenters.

“VXI is proud to partner with Blue Energy as the company unlocks the largest underutilized resource civilization has: nuclear power,” said Orin Hoffman, Managing Director of VXI Capital and Board Director at Blue Energy. “By delivering abundant, affordable nuclear power Blue Energy is perfectly positioned to meet rapidly increasing near-term energy demand from data centers and advanced manufacturing. Our investment reflects our confidence that, by building the world’s first project-financed nuclear power plant, Blue Energy will rewrite the playbook for nuclear power’s next era.” 

“The Blue Energy team has made remarkable progress de-risking the single hardest problem in nuclear — the cost structure that makes it project-financeable,” said Michael Kearney, General Partner at Engine Ventures and Board Director at Blue Energy. “Their manufacturing and development approach is what finally positions nuclear to run down the cost curve necessary for rapid deployment to meet this moment of demand growth, and we couldn’t be more excited to back them on that path.”

The U.S. Nuclear Regulatory Commission (NRC) recently approved Blue Energy’s innovative approach to resequencing major phases of nuclear plant construction by initially energizing turbines with natural gas before conversion to nuclear power. This approval marks an important regulatory milestone and establishes a new precedent for phased nuclear plant construction in the United States.

About Blue Energy
Founded in 2023, Blue Energy develops financeable, turnkey nuclear power plants compatible with leading reactor technology. Our proprietary lower cost of capital solution and offsite pre-fabrication accelerates new nuclear deployment – making it predictable, faster and more affordable. We will deliver baseload power competitive with fossil fuels and renewables to meet unprecedented global demand. Blue Energy’s world-class team has extensive experience in nuclear construction, licensing, engineering, and development. We stem from MIT’s Nuclear Science & Engineering Department and are backed by VXI Capital, Engine Ventures, At One Ventures and Tamarack Global. Visit www.blueenergy.co or follow us on LinkedIn.

SOURCE Blue Energy

DUBAI, UAE, April 21, 2026 — Infoquest, the custom sourcing expert network, announces the official opening of its Americas headquarters. The office marks the firm’s first physical presence in the Western Hemisphere and establishes a dedicated hub for all Americas-based client operations across the United States, Canada, and Latin America.

Founded in 2023, Infoquest has built a rapidly growing expert network serving leading consulting firms, private equity investors, and corporate strategy teams across EMEA. The Americas’ expansion was driven by a sustained increase in demand from North American clients requiring expert network coverage, combined with the need to align the company’s operations with its Americas client base.

This expansion addresses the limits of traditional expert databases, which struggle to provide the precision needed for specific research demands. Infoquest overcomes this by custom-sourcing every expert from scratch, ensuring exact profile matches for each brief. This approach delivers higher relevance and faster turnaround, regardless of sector. The new Americas office extends this bespoke sourcing capability to the Western Hemisphere with a dedicated regional team.

“Infoquest grew from zero to 50+ FTEs in under three years for a reason. We built a next-gen network on custom sourcing because the right expert usually isn’t pre-registered anywhere, and even when they are, legacy networks miss the context behind client requests. The Americas is where that demand is growing fastest. If your team is tired of settling for close enough, we’re here now.” 

Omar Yamak, CEO, Infoquest

The Americas office launches with all core Infoquest service lines. The firm serves clients across management consulting, private equity, venture capital, and corporate strategy, with coverage spanning energy, infrastructure, financial services, technology, consumer markets, and more throughout the hemisphere.

To mark the opening, Infoquest is offering new Americas clients two complimentary expert calls on their first project. Full details are available at Infoquest Americas.

ABOUT INFOQUEST

Infoquest is a custom sourcing expert network founded in 2023, operating across GCC, EMEA, and the Americas. The firm connects consulting firms, investors, and corporate clients with verified subject matter experts for primary research, due diligence, market intelligence, and strategic advisory, delivered in under two hours, at approximately 30% below market rate. For more information, visit iqnetwork.co.

Media Contact: Nabil Kanaan, Senior Marketing Associate, Infoquest | [email protected]

Photo – https://mma.prnewswire.com/media/2958109/Infoquest_in_the_americas.jpg
Logo – https://mma.prnewswire.com/media/2958108/Infoquest_Logo.jpg

SOURCE INFOQUEST

Strategic joint venture aims to enhance liquidity, transparency, and investor confidence in Stake’s real estate offerings in the UAE

DUBAI, UAE, April 21, 2026 — Stake, the MENA region’s leading digital real estate investment platform, and ACE & Company, a Swiss-headquartered global investment group focused on private markets, with more than $2.0 billion in assets under management, today announced a strategic partnership to support the development of liquidity solutions for investors in Stake products. The agreement will focus initially on the platform’s real estate portfolio in the UAE, held through Prescribed Companies, the equivalent of Special Purpose Vehicles (SPVs) in DIFC.

The initiative is intended to create a more liquid, transparent, and efficient marketplace for investors seeking exposure to fractional real estate opportunities through Stake’s platform. By combining Stake’s innovative access model with ACE & Company’s longstanding experience in private market investing and secondary transactions, the partnership aims to strengthen the investment ecosystem around fractional ownership structures in the UAE.

The joint venture reflects both firms’ confidence in the long-term fundamentals of the UAE. At a time of heightened regional uncertainty, the UAE continues to distinguish itself through economic resilience, political stability, high-quality infrastructure, and sustained global investor interest. These attributes have helped position the country as one of the region’s most compelling destinations for long-term real estate capital.

Through the planned secondary infrastructure framework, investors in Stake products are expected to benefit from greater flexibility in managing their holdings, improved visibility around market pricing, and clearer pathways to liquidity. In turn, the broader market stands to benefit from enhanced stability, stronger price discovery, and increased participation and confidence in fractional real estate as an investable asset class. The framework operates within Stake’s existing DFSA-approved regulatory permissions, providing investors with established oversight and regulatory clarity. Stake is regulated by the DFSA, the independent regulator for business conducted from or within DIFC.

For Stake, the partnership marks an important step in the continued evolution of its platform, extending beyond access to ownership and toward the development of more mature market infrastructure. For ACE & Company, the collaboration draws on its extensive experience in private equity and secondaries to help unlock liquidity solutions in a fast-growing segment of the alternative investment landscape. The DIFC’s established private markets framework, and its Prescribed Company regulations in particular, have been central to enabling this model, providing the institutional and legal infrastructure on which this secondary transfer facility innovation is built.

Manar Mahmassani, Co-Founder and Co-CEO of Stake said:
“The UAE has always rewarded those who invest in it with conviction, and that’s exactly what this partnership represents. Stake was born in crisis. We launched during COVID, when global real estate markets were struggling and Dubai‘s property industry was at its low point. What we saw was a market that is far from broken, but fundamentally sound, going through a temporary challenge. That conviction has never left us. Today, the world is watching the region, and we want to be unambiguous about where we stand: we are long Dubai, and we are long the UAE. This is not the moment to retreat: it’s the moment to build the institutional infrastructure this market deserves. That’s exactly what this partnership is all about – a mature, resilient market attracting institutional confidence and capital committed for the long run.”

Sherif El Halwagy, Partner and Co-Founder at ACE & Company said:

“Drawing on almost two decades of experience in offering liquidity to investors across private markets ecosystems via secondaries, we see a tremendous opportunity in real estate secondaries in the UAE. This partnership reflects our conviction in the country’s long-term fundamentals and our disciplined approach to capital deployment in high-quality assets. We look forward to further strengthening our relationships with investors and partners across the region.”

The partnership is designed to benefit all stakeholders across the ecosystem. Existing investors gain added optionality and transparency, prospective investors gain greater confidence in the structure, and the market benefits from stronger liquidity mechanisms, a scalable source of permanent/long-term capital and a more institutionalized framework for participation.

As fractional ownership continues to gain traction globally, Stake and ACE & Company believe that robust secondary infrastructure will play a critical role in supporting the sector’s long-term growth. The joint venture represents a shared commitment not only to product innovation, but also to building the underlying market architecture needed to support sustainable expansion in the UAE and beyond.

About Stake

Founded in the UAE in 2021, Stake is a DIFC-based fintech company and the leading real estate investment platform in the MENA region and beyond. Regulated by the Dubai Financial Services Authority (DFSA) for fractional properties, and by the Capital Market Authority (CMA) in Saudi Arabia for fund distribution, Stake has built a community spanning over 2 million users from 211+ nationalities and has enabled over 450,000 investments across 600+ properties and 4 private real estate funds, paying out over AED 70 million in rental income and surpassing AED 1.5 billion in real estate transactions to date.

About ACE & Company

ACE & Company is a global investment group focused on private markets, with more than $2.0 billion in assets under management and over 20 years of investment experience. The firm invests across three core strategies—Venture, Independent Sponsors, and Secondaries—providing diversified exposure and differentiated return opportunities across the private markets lifecycle. Headquartered in Geneva, ACE & Company has offices in Zurich, London, New York, and Cairo.

Media Contacts
Stake
Ozge Onur
VP Marketing
[email protected]
+971.52.846.9054

ACE & Company
Elia Innamorati
Investor Relations
[email protected]
+41.22.311.3333

Photo: https://mma.prnewswire.com/media/2960201/Stake_ACE_Company.jpg
Logo:  https://mma.prnewswire.com/media/2955803/5917553/ACE_and_Company_Logo.jpg

SOURCE ACE & Company

The AI-native books platform backed by KAUST Innovation Ventures, DisrupTech Ventures, and a coalition of leading investors is transforming the way people read, bringing books to life as living, interactive aiBook™ experiences

SUNNYVALE, Calif., April 20, 2026 — Sinai.ai, an AI-native books platform, today announced the close of its $1.45M pre-seed funding round, led by KAUST Innovation Ventures (KIV) and DisrupTech Ventures, with participation from Maza Ventures and YOUXEL Ventures, alongside a coalition of angel investors. The capital will fund proprietary tech, AI infrastructure, user acquisition, and licensing.

The $150 billion global book market has seen little innovation in format for decades. Sinai was built to change that. At the heart of the platform is the aiBook™, a trademarked, patent-backed book format built on 100% licensed, full-text content. Readers can converse with their book in real time, generate study guides and quizzes, access titles across multiple languages, and switch between reading and listening. Sinai is launching with thousands of titles, having already secured partnerships with double-digit publishers, including several prominent names in the industry.

Investor Perspectives

“We strongly believe that AI will fundamentally reshape a wide range of industries, and the book industry is long overdue for meaningful innovation. For over two decades, the core format of books has remained largely unchanged. What the Sinai.ai team is building introduces a truly new paradigm — transforming books into interactive, intelligent experiences where readers can engage, learn, and explore in entirely new ways. We are particularly excited about the team and their ability to execute on a vision that sits at the intersection of content, technology, and user experience. We are always proud to back Egyptian founders who are building category-defining companies and pushing the boundaries of innovation beyond local markets.”
— Mohamed El Sayed Okasha, DisrupTech Ventures

“What drew me to Sinai.ai is that they’re approaching a huge, old industry with respect and clarity. Publishing has been around for centuries, and for good reason, but much of how it operates hasn’t evolved at the pace of technology. Instead of trying to break it, Sinai.ai is working alongside it, using AI to modernize how books are created, produced, and distributed. That’s a harder path. It requires understanding the incentives of everyone involved and building something that fits into a real ecosystem, not just replacing it. But it’s also the more enduring one. The companies that last are often the ones that reshape industries from within, and Sinai.ai feels like it’s doing exactly that.”
— Tambi Jalouqa, Maza Ventures

About the Team

Sinai.ai was co-founded by five individuals: Ahmed Kamel (CEO), a serial tech entrepreneur with post-graduate studies in AI and innovation at Stanford; Mohamed Elshamy (CRO), Yale MBA, with experience at Google, McKinsey, and Meta; Mohamed Elshenawy (CTO), PhD in AI from the University of Toronto, and led AI teams in different ventures; Hana Malhas (CFO), University of Michigan MBA, with deep experience in creative industries; and Abdullah Moatasem (CCO), creative director with credits at Warner Bros., Netflix, and Disney+.

Media Contact
Hana Malhas
6692369534
[email protected]
www.sinai.ai

SOURCE Sinai.ai Inc.

The ASPCA and Best Friends will work alongside LAAS leadership to implement strategic improvements designed to better serve the Los Angeles community and its animals. The initiative will focus on three core priorities:

• Preventing unnecessary shelter intake via community engagement;
• Improving in-shelter care and operational efficiency to ensure animals receive timely, coordinated care; and
• Increasing positive outcomes for animals such as adoptions, fostering and reunification with owners.

The ASPCA and Best Friends are committed to supporting LAAS over an initial three-year period, and, as part of the agreement, LAAS will commit to maintaining key positions and continuing programmatic advancements for an additional three years following the grant period, ensuring long-term impact.

“Animal sheltering nationwide has undergone a dramatic shift in recent years—from simply housing animals to prioritizing positive outcomes,” said Mayor Karen Bass. “This historic investment will enable LA Animal Services staff to place an even greater emphasis on those positive outcomes and position the department at the forefront of accountable, transparent sheltering—all with the goal of supporting pet owners and helping animals find loving homes. I’m grateful to the ASPCA and Best Friends Animal Society for these visionary grants, which will support the department’s dedicated staff, volunteers and New Hope partners as they advance humane care and help keep people and pets together.”

“If we can help LA Animal Services—one of the largest shelter systems in the country—build a future where every animal receives the care, compassion and safety they deserve,” said Matt Bershadker, ASPCA President & CEO, “we won’t just be helping transform one city, we’ll be showing communities across the country what’s possible.”

“Through collaboration, we can create permanent, systemic change in Los Angeles,” said Julie Castle, CEO, Best Friends Animal Society. “This will be a moment in history we look back on, knowing animal welfare in Los Angeles was forever changed by this groundbreaking partnership.”

“The combined support from the ASPCA and Best Friends extends beyond the immediate operations needs of LA Animal Services,” said Annette G. Ramirez, Interim General Manager for LA Animal Services. “It demonstrates a commitment to a renewed vision for animal welfare across the city to keep pets and people together, by providing support to shelter staff, and creating a faster, more efficient path for animals in our care to find loving homes.”

Through this proposed initiative, LAAS will receive $7 million in grant funding from both the ASPCA and Best Friends to support more than 20 critical staffing roles, including expanded adoption and foster teams and dedicated specialists for community cat programs. In addition, the ASPCA and Best Friends will embed four experienced staff members within LAAS facilities to provide hands-on support with training, program development and implementation, and animal health and safety.

The initiative will also introduce enhanced intake strategies, expand foster care capacity, and strengthen return-to-owner efforts, including field-based reunifications. Comprehensive training will be provided to LAAS staff, covering areas such as animal care, shelter medicine, adoption services, data management, volunteer engagement and community outreach.

As one of the largest municipal shelters in the country, LAAS serves approximately 50,000 animals and responds to more than 20,000 emergency calls involving animals and people in danger. LAAS has worked diligently to reduce overcrowding across its six shelters by offering reduced adoption fees for dogs and cats, partnering with animal-loving organizations to host special adoption weekends, and working closely with New Hope Partners, which has resulted in a placement rate of 90% or greater for dogs since 2017. The Department also provides resources for Angelenos to spay/neuter their pet and provides free pet food assistance through the weekly Pet Food Pantry, which helped more than 21,646 pets last year. Since January 2025, LAAS has continued to build upon the collaborative work surrounding fostering and pet reunification best practices, which began with the ASPCA, Best Friends and other animal welfare organizations in response to helping pets and their families affected by the Palisades fire.

This initiative marks the first time the ASPCA and Best Friends have combined resources at this scale to support a single shelter system, although both organizations have been actively supporting animal welfare efforts in the Los Angeles area for decades. Since 2014, the ASPCA has been working to assist animals in underserved communities across Los Angeles through its direct care services and programmatic investments, as well as by partnering with city, county and private agencies to provide more than $16 million in grant funding. To date, the ASPCA has spayed/neutered more than 167,000 Los Angeles pets and shelter animals at its ASPCA Spay/Neuter Clinic in South Los Angeles; provided more than 56,000 primary pet care appointments at its stationary and mobile clinics; prevented more than 14,000 kittens from entering crowded shelters through its kitten foster program; safely transported more than 70,000 dogs and cats from Los Angeles area shelters to other organizations for a better chance of adoption; and advocated for stronger animal welfare laws at the local, regional and state level.

Best Friends has been working on behalf of Los Angeles’s pets since 1992 when it started volunteer programs with LAAS. Since that time, Best Friends has invested more than $80 million to support lifesaving programs across Los Angeles—conserving local resources and improving outcomes for the most at-risk animals—by partnering with LAAS through grants and hands-on operational support. Since 2012, Best Friends has expanded spay/neuter and community services (including vaccines, microchips, and high-volume spay/neuter and TNVR surgeries at no cost); founded and continues to lead the No-Kill Los Angeles (NKLA) Coalition of 160 shelters and rescue groups to coordinate solutions with LAAS leadership; and operated key adoption and spay/neuter centers under city contracts (Northeast Valley beginning in 2012 and Jefferson Park beginning in 2018). Best Friends has directly transferred more than 55,000 animals from LAAS shelters to increase lifesaving and strengthened volunteer and foster capacity (including 1.6 million volunteer hours and fast-tracking neonatal kittens into foster during kitten season). Together, these strategies have supported LAAS in saving 36,783 cats and dogs in 2025.

Together, the ASPCA and Best Friends Animal Society are partnering with LAAS to strengthen care for animals and better support the community. By combining funding, expertise and on-the-ground support, this effort is designed to deliver immediate improvements while building a more effective and sustainable shelter system for the future.

About the ASPCA^®
The ASPCA^® (The American Society for the Prevention of Cruelty to Animals^®) believes every animal deserves to live free from suffering. For 160 years, we’ve been on the frontlines to save, transform and protect millions of lives in the fight against animal cruelty. As the nation’s first and leading animal welfare organization, we assist animals in need through on-the-ground disaster and cruelty interventions, behavioral rehabilitation, animal relocation and placement, legal and legislative advocacy, and the advancement of the sheltering and veterinary communities through research, training and resources. As a 501(c)(3) not-for-profit corporation with more than 2 million supporters nationwide, our commitment to eliminating animal cruelty is unwavering. For more information, visit aspca.org, and follow the ASPCA on Facebook, X, Instagram, LinkedIn and TikTok.

About Best Friends Animal Society^®
Best Friends Animal Society is a leading animal welfare organization dedicated to saving the lives of dogs and cats in America’s shelters and making the entire country no-kill. Founded in 1984, Best Friends runs lifesaving facilities and programs nationwide in partnership with more than 6,000 shelters and rescue organizations. From our headquarters in Kanab, Utah, we also operate the nation’s largest no-kill animal sanctuary — a destination that brings our mission to life for thousands of visitors each year. We maintain the most comprehensive animal sheltering data in the country and make it accessible to the public — empowering communities with critical insights into the needs of their local shelters and how they can help. We believe every dog and cat deserves a home. And we believe that, by working together, we can Save Them All®.

About LA Animal Services
LA Animal Services promotes and protects the health, safety, and welfare of animals and the people who love them, and is one of the largest municipal shelter systems in the United States. With six Centers across the City, LA Animal Services serves approximately 50,000 animals annually and responds to 20,000 emergency calls involving animals or people in danger. For LA Animal Services, there’s no place like home so the Department provides resources to keep pets and families together; helps lost pets get home quickly without having to enter the shelter system; provides pet food assistance; and continues to build on a strong adoption and foster program so pets find loving homes or are placed in foster care. Visit our link.tree for helpful links to the services and resources available to you and your companion animals. Connect with LA Animal Services and follow us on Facebook, Instagram, and X.

SOURCE ASPCA

STOCKHOLM, Sweden, April 20, 2026 — Between 13 April 2026 and 17 April 2026 EQT AB (LEI code 213800U7P9GOIRKCTB34) (“EQT”) has repurchased in total 318,372 own ordinary shares (ISIN: SE0012853455).

The repurchases form part of the repurchase program of a maximum of 3,005,071 own ordinary shares for a total maximum amount of SEK 2,500,000,000 that EQT announced on 4 March 2026. The repurchase program, which runs between 4 March 2026 and 8 May 2026, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No 2016/1052.

EQT ordinary shares have been repurchased as follows:

All acquisitions have been carried out on Nasdaq Stockholm by Skandinaviska Enskilda Banken AB on behalf of EQT.

Following the above acquisitions and as of 17 April 2026, the number of shares in EQT, including EQT’s holding of own shares is set out in the table below.

1) Total number of shares in EQT AB, i.e. including the number of shares owned by EQT AB
2) EQT AB shares owned by EQT AB are not entitled to dividends or carry votes at shareholders’ meetings

A full breakdown of the transactions is attached to this announcement.

Contact

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/repurchases-of-shares-by-eqt-ab-during-week-16–2026,c4337261

The following files are available for download:

NEW YORK, 20. April 2026 — Pulnovo Medical, ein Pionier für bahnbrechende Therapien zur Behandlung von pulmonaler Hypertonie und Herzinsuffizienz, gab heute den erfolgreichen Abschluss einer überzeichneten strategischen Finanzierungsrunde von 100 Millionen US-Dollar bekannt, an der sich Medtronic, eines der weltweit größten Medizintechnikunternehmen, als federführender Investor mit anhaltender Unterstützung von bestehenden Investoren wie EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed und Lilly Asia Ventures beteiligte. Pulnovo begrüßt außerdem neue Investoren, darunter HSG (ehemals Sequoia China) und andere prominente globale Investoren. Diese Finanzierung stellt einen bedeutenden Meilenstein auf dem globalen Wachstumskurs von Pulnovo dar und spiegelt das starke Vertrauen führender strategischer sowie institutioneller Investoren in die Technologie des Unternehmens, seine klinischen Fortschritte sowie seine langfristige Vision wider.

Gesondert davon haben Medtronic und Pulnovo eine kommerzielle Vereinbarung geschlossen, die potenzielle zukünftige Vermarktungsmöglichkeiten vorsieht. Die Vereinbarung soll die kommerziellen Synergien zwischen Pulnovo und Medtronic sowie die besondere und umfassende globale Vermarktungskompetenz von Medtronic nutzen.

Pulnovos firmeneigenes Pulmonary Artery Denervation (PADN) System setzt an einem zentralen zugrunde liegenden Mechanismus kardiopulmonaler Erkrankungen an und hat signifikante klinische Vorteile gezeigt, darunter Verbesserungen der funktionellen Kapazität sowie der Behandlungsergebnisse der Patienten. Bis heute hat das Unternehmen weltweit etwa 1500 PADN-Verfahren durchgeführt und in sieben Ländern behördliche Zulassungen erhalten, was seine wachsende internationale Präsenz untermauert. Pulnovo treibt die Vermarktung in der Europäischen Union, im Nahen Osten und in China voran.

In den Vereinigten Staaten hat Pulnovo die Breakthrough-Device-Auszeichnung der FDA erhalten und zwei vollständig genehmigte Studien im Rahmen einer Investigational Device Exemption (IDE) eingeleitet, die beide von Dr. Gregg Stone, leitendem Hochschullehrer und Professor am Mount Sinai, geleitet werden.

„Durch die Verbindung von Branchenexpertise und langfristigem Kapital baut Pulnovo ein skalierbares Wachstumsmodell auf, das auf firmeneigener Innovation, globaler klinischer Entwicklung sowie strategischen Partnerschaften innerhalb des Ökosystems basiert. Diese Finanzierung markiert einen entscheidenden Übergang von einer produktgetriebenen Phase zu einer vollständig integrierten globalen Plattform. Während wir unsere Fähigkeiten sowohl auf klinischer als auch auf technologischer Ebene weiter stärken, bleiben wir unserem Ziel verpflichtet, Patienten weltweit bedeutsame Innovationen bereitzustellen.”

– Cynthia Chen, Vorsitzende und Präsidentin, Pulnovo Medical

EINE STRATEGISCHE PARTNERSCHAFT FÜR WELTWEITE SKALIERUNG

Diese Finanzierung stärkt Pulnovos strategische Zusammenarbeit mit globalen Industrie- und Kapitalpartnern und verbessert die Fähigkeit des Unternehmens, die klinische Entwicklung voranzutreiben, globale Zulassungsstrategien umzusetzen sowie seine kommerziellen Aktivitäten auszubauen.

Die Erlöse aus dieser Finanzierung werden zur Unterstützung der laufenden klinischen Entwicklung, für weltweite Zulassungsanträge, die internationale Vermarktung sowie weitere Investitionen in die technologische Kernplattform des Unternehmens verwendet.

Im Zuge des Ausbaus des globalen Führungsteams ist Andre Xiao als Strategieleiter dem Unternehmen beigetreten, wo er die globale Finanzierung und Strategie leiten wird. In enger Zusammenarbeit mit dem Verwaltungsrat wird Andre eine wichtige Rolle dabei spielen, Pulnovos Anbindung an die globalen Kapitalmärkte sowie Branchennetzwerke zu stärken und damit die nächste Wachstumsphase des Unternehmens zu unterstützen.

Andre verfügt über umfangreiche Erfahrung in Healthcare-Investments und auf den globalen Kapitalmärkten, darunter frühere Positionen bei führenden Investmenthäusern wie Citadel sowie Millennium Management, wo er sich auf globale Investitionen im Bereich Medizintechnik spezialisiert hat.

INFORMATIONEN ZUR PULMONALEN ARTERIENDENERVIERUNG

Pulnovos firmeneigenes Pulmonary Artery Denervation (PADN) System ist die erste minimal-invasive Therapie ihrer Klasse. Sie wurde entwickelt, um die überaktivierte Aktivität des sympathischen Nervensystems zu modulieren, die zum Umbau der pulmonalen Gefäße und zum Fortschreiten kardiopulmonaler Erkrankungen beiträgt. Da PADN auf einen zentralen Krankheitsmechanismus abzielt, hat es in globalen Studien klinisch bedeutsame Ergebnisse gezeigt, darunter Verbesserungen der funktionellen Kapazität und eine Verringerung der wichtigsten unerwünschten klinischen Ereignisse.

Die Therapie wurde in mehreren internationalen klinischen Leitlinien anerkannt, darunter durch ihre Aufnahme in die Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) und der Europäischen Atemwegsgesellschaft (ERS) aus dem Jahr 2022 zur Diagnose und Behandlung der pulmonalen Hypertonie, und wurde bislang in insgesamt sieben klinischen Leitlinien erwähnt.

Es laufen klinische Studien in verschiedenen Regionen, darunter Studien in Europa und Asien, die kurz vor dem Abschluss stehen, sowie die PULSE-LHD IDE-Studie in den Vereinigten Staaten, die vor kurzem begonnen wurde. Zusammen werden diese Studien voraussichtlich die klinische Evidenzbasis für PADN weiter stärken und das Potenzial der Therapie untermauern, einen erheblichen ungedeckten medizinischen Bedarf bei Patienten mit Herzinsuffizienz und verwandten kardiopulmonalen Erkrankungen zu decken.

Informationen zu Pulnovo Medical

Pulnovo Medical ist ein innovatives Medizintechnikunternehmen, das sich der Entwicklung interventioneller Therapien für pulmonale Hypertonie und Herzinsuffizienz widmet. Ausgerichtet auf klinischen Nutzen entwickelt das Unternehmen bahnbrechende Lösungen auf Grundlage seiner firmeneigenen Technologieplattform, mit einem Schwerpunkt auf globaler klinischer Entwicklung und Vermarktung, um die Behandlungsergebnisse von Patienten weltweit zu verbessern.

PALO ALTO, Calif., April 20, 2026 — Jonathan Tower today announced he is stepping down from Prosperity7 Ventures, the $3 billion global venture capital arm funded by Aramco, following his successful tenure as Regional Managing Director and Head of U.S. Ventures. The departure follows a period of strategic growth and strong performance of Prosperity7 in the U.S. under Tower’s leadership.

Upon joining Prosperity7 in early 2022 as its first U.S.-based executive, Tower launched and scaled the firm’s North American venture operations. During his tenure, he led the opening of Prosperity7’s Palo Alto office and New York offices, recruited a 14-person U.S. investment team, and helped establish the firm’s presence in the venture ecosystem.

Under Tower’s leadership, Prosperity7 deployed over $600 million across more than 60 companies spanning AI infrastructure, data platforms, robotics, cybersecurity, and enterprise software, including Cohere, Hammerspace, Together AI, SingleStore, Cart.com, Artera, AppOmni, Cowbell, Nile, and Jeeves.

“We built the U.S. platform from a blank slate into a fully formed venture business with a strong team and a high-conviction portfolio,” said Tower. “With AI reshaping every industry, this feels like the right moment to build again.”

Looking ahead, Tower is launching a new AI-native venture platform focused on backing founders building the next generation of AI companies and infrastructure. The new platform will combine a thesis-driven investment strategy with a media component designed to share research and insights with the broader technology and entrepreneurial community.

“Artificial Intelligence is reshaping not just the companies in which we invest – it’s changing how venture firms themselves will need to operate and compete. The venture playbook that defined the last decade won’t define the next,” Tower added. “I’m focused on building a platform that reflects that dramatic shift.”

Tower’s full reflections on his tenure and plans ahead are available on his blog at https://jtower09.medium.com/.

SOURCE Jonathan Tower